Patents Assigned to Oncotherapy Science, Inc.
  • Patent number: 9132176
    Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 15, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
  • Patent number: 9125849
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.
    Type: Grant
    Filed: November 25, 2011
    Date of Patent: September 8, 2015
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
  • Patent number: 9119800
    Abstract: The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and/or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: September 1, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura
  • Patent number: 9120749
    Abstract: The present invention directs a compound represented by formula (I).
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: September 1, 2015
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yo Matsuo, Shoji Hisada, Yusuke Nakamura, Feryan Ahmed, Raymond Huntley, Joel R. Walker, Helene Decornez
  • Patent number: 9115207
    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: August 25, 2015
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 9073021
    Abstract: In preparation of an emulsion by causing a mixture to flow from one syringe through a connector into another syringe, an object is to prevent the air from being entrained into cylinders and prepare the emulsion containing no air bubble, and another object is to easily prepare a homogeneous emulsion. Provided is a syringe pressing apparatus, including: a syringe fixing mechanism for fixing two syringes to a casing, the two syringes being coupled to each other through a connector; a pressing mechanism for alternately pressing syringe plungers of the two syringes; and a plunger-pressure-measuring device for measuring a pressure with which the pressing mechanism presses the syringe plungers.
    Type: Grant
    Filed: September 7, 2009
    Date of Patent: July 7, 2015
    Assignees: ONCOTHERAPY SCIENCE, INC., THE UNIVERSITY OF TOKYO
    Inventors: Yusuke Nakamura, Yuichi Iwai, Kouji Yoshida
  • Patent number: 9073968
    Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: July 7, 2015
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yasuharu Nishimura, Kazunori Yokomine, Takuya Tsunoda, Yusuke Nakamura
  • Patent number: 9067973
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: June 30, 2015
    Assignee: Oncotherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa
  • Patent number: 9067937
    Abstract: The present invention directs a compound represented by formula (I).
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: June 30, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yo Matsuo, Shoji Hisada, Yusuke Nakamura, Feryan Ahmed, Joel R. Walker, Raymond Huntley
  • Patent number: 9056890
    Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: June 16, 2015
    Assignee: OncoTherapy Science Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 9045557
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: June 2, 2015
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Patent number: 9017669
    Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: April 28, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuhiro Shiba, Hiroki Yoshioka, Shinji Yamamoto, Aiko Kudo, Ryuji Ohsawa, Pohsing Ng, Yusuke Nakamura, Keigo Endo
  • Patent number: 9017688
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: April 28, 2015
    Assignee: Oncotherapy Science, Inc.
    Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
  • Patent number: 8975229
    Abstract: The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: March 10, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Motokazu Tsujikawa, Yusuke Nakamura, Takuya Tsunoda
  • Patent number: 8975086
    Abstract: The present invention provides therapeutic agents and methods for treating cancer using the polypeptides composed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: March 10, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Akira Togashi
  • Patent number: 8962648
    Abstract: Tricyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: February 24, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yo Matsuo, Shoji Hisada, Feryan Ahmed, Raymond Huntley, Zohreh Sajjadi-Hashemi, David M. Jenkins, Robert B. Kargbo, Wenge Cui, Polivina Jolicia F. Gauuan, Joel R. Walker, Helene Decornez, Mahender Gurram
  • Patent number: 8951975
    Abstract: Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: February 10, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 8933014
    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: January 13, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 8883966
    Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: November 11, 2014
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
  • Patent number: 8871719
    Abstract: Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: October 28, 2014
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe